ArticleScientific reports2026
A computational rule-based model of MAPK/ERK system regulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The MAPK/ERK pathway coordinates multiple cellular functions, including proliferation, apoptosis, and motility, yet it is frequently modeled as a one-purpose cascade. Pathway complexity stems from the existence of isoforms that are regulated differently and have specific interacting partners. Here, we overcome combinatorial complexity by constructing a rule-based model of the MAPK/ERK pathway that accounts for differential regulation of MEK and RAF isoforms and RAF interactions with 14-3-3 proteins. The model addresses signaling based on the enzymatic cascade as well as regulatory protein-protein interactions. We propose that at low concentrations of growth factors, RAS is activated only in a portion of the membrane. This allows the model to reconcile the observed graded and switch-like responses observed at the upper (RAS and RAF) and the lowest (ERK) tiers of the pathway, respectively. We demonstrate that functional differences between BRAF and CRAF, or ARAF, can arise from their distinct interactions with 14-3-3. The 14-3-3 dimers inhibit all RAF monomers in the closed form and preferentially stabilize BRAF-CRAF or BRAF-ARAF dimers and may not stabilize RAF dimers without BRAF. The constructed model is used to explore qualitative differences in MAPK/ERK pathway signaling across different cell lines. The exploration starts from the nominal model parameters chosen to reflect a generic cell.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.